Niagen Bioscience Inc
NASDAQ:NAGEBiotechnology
+$0.11 today
- Market cap
- $153.64M
- Beta
- 2.06
- P/E (TTM)
- 14.9
- EPS (TTM)
- $0.23
Volume 0.52M
Average 0.86M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Niagen Bioscience Inc
NASDAQ:NAGE
Intrinsic Alpha fair value
Locked
Current Price
$1.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +15.4% (5yr)1 analysts |
| Revenue | N/A | N/A | +21.6% | +12.5% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | +15.0% (5yr)1 analysts |
| EBIT | N/A | N/A | N/A | +25.4% (5yr)1 analysts |
Analysis
Recent growth has been strongest in Revenue at +21.6% over three years. Forward estimates point to EBIT at +25.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
KalVista Pharmaceuticals, Inc. NASDAQ:KALV | $1.44B | $27.00 | Not rated | -9.9 | +96.94% |
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | $897.52M | $10.64 | Not rated | -24.1 | +14.49% |
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | $837.18M | $44.46 | Undervalued | 1.7 | +2.04% |
Olema Pharmaceuticals, Inc. NASDAQ:OLMA | $662.30M | $7.56 | Not rated | -5.1 | -63.66% |
Zevra Therapeutics, Inc. NASDAQ:ZVRA | $540.30M | $9.08 | Overvalued | 6.1 | -4.13% |
REGENXBIO Inc. NASDAQ:RGNX | $505.18M | $7.64 | Not rated | -1.5 | -33.58% |
Prothena Corporation plc NASDAQ:PRTA | $419.01M | $8.16 | Not rated | -3.1 | -16.42% |
Keros Therapeutics, Inc. NASDAQ:KROS | $202.13M | $10.30 | Undervalued | -4.6 | -28.83% |
Akebia Therapeutics, Inc. NASDAQ:AKBA | $131.67M | $0.47 | Undervalued | -13.3 | -74.28% |
Continue the stock analysis
Jump to another research area for this company.